title: Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.
abstract: The impact of ABO incompatibility on clinical outcomes following haematopoietic SCT (HSCT) remains controversial. This retrospective study assessed the effect of ABO mismatch on transplant outcomes and transfusion requirements in 594 patients undergoing reduced-intensity conditioned (RIC) HSCT with alemtuzumab in three UK transplant centres. We found no significant effects of minor, major or bidirectional ABO mismatch on overall survival, relapse-free survival, nonrelapse mortality or relapse incidence. Although the rate of acute GVHD was unaffected by ABO mismatch, the incidence of extensive chronic GVHD was higher in patients with minor and major mismatch compared with those who were ABO matched (hazard ratio (HR) 1.74, P=0.032 for minor, HR 1.69 P=0.0036 for major mismatch). Red cell and platelet transfusion requirements in the first 100 days post transplant did not differ by ABO mismatch. In this large UK series, ABO mismatch in RIC HSCT has no clinically significant effect on survival outcomes but appears to modify susceptibility to extensive chronic GVHD.
authors: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors: C K
authors: CK
authors: Brierley
authors: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors: T J
authors: TJ
authors: Littlewood
authors: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors: A J
authors: AJ
authors: Peniket
authors: Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
authors: R
authors: R
authors: Gregg
authors: Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
authors: J
authors: J
authors: Ward
authors: Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
authors: A
authors: A
authors: Clark
authors: Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
authors: A
authors: A
authors: Parker
authors: Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
authors: R
authors: R
authors: Malladi
authors: Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK.
authors: P
authors: P
authors: Medd
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology* / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000017:ABO Blood-Group System; D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab